Ysios capital participates in $68M round in Kala pharmaceuticals

, , ,
Integral service around a transaction
BY : Diego GutiérrezApril Tue, 2016
Ysios capital, the leading private equity manager in the biotech sector in Spain, announced on 14 April that it has participated in a $68M round in the U.S. Kala Pharmaceuticals,  specialising in the development of innovative treatments for eye diseases. We take a look at the investments made by this fund manager.


Investments made by Ysios Capital

Since its launch in 2009 Ysios has participated in 18 companies and 25 financing rounds and has divested 5 companies.

 After a few years in which the number of participations had declined, last year Ysios made a strong commitment to biotechnology and participated in 4 rounds, a figure it had not reached since 2009, when the fund was created.

Last year it also led one of the largest deals in the biotech sector in Spain's history, a €36.6M capital increase in Sanifit, which is developing a drug for the treatment of cardiovascular diseases related to calcification in patients with End Stage Renal Disease (ESRD). 

Ysios has made both seed and postIPO investments with the objective of balancing risk and liquidity. It also invests in different biotech sub-sectors with different time-to-market horizons, capital requirements and return risk traits.

In terms of the countries in which it has invested, in addition to Spain, we find countries such as the USA, Switzerland, the Netherlands and Great Britain.

Ysios aims to become an international benchmark investor in the biotechnology sector and the participation in Kala pharmaceuticals, being the largest financing round ever closed by Ysios reinforces this position.

Investments in 2016

In addition to the investment in the American company Kala pharmaceuticals, this year Ysios has also invested in the Spanish company Inbiomotion and in Aelix Therapeutics.

Ysios had already invested in Inbiomotion, leading the round in 2012, this time the round has been led by la Caixa.

 Inbiomotion develops diagnostic assays to predict cancer patients' risk of bone metastasis. 

Aelix Therapeutics, a newly created spin-off of Hivacat, specialises in the development of immunotherapies against HIV infection.

In addition, as we mentioned in a post a few weeks ago, Ysios has added new investors to its fund. YsiosBioFundIIincluding theBanco Sabadell and some pension funds.


Ysios has made a number of successful divestments such as the sale Swiss medical device company Endosense to US giant St.Jude Medical in 2013 for which it received €16M, three times more than it had invested.

For Ysios, Endosense was its second divestment, after it also exited Biovex, a Boston-based biotech specialising in cancer therapies, at a good profit in 2011.

Last year Ysios sold a minority stake in the company's share capital. AM-Pharmay an exclusive option to purchase the 100% from Pfizer.

Since its creation, AM-Pharma has raised €67 million, including €12.2 million in September 2014 to complete the development of the Phase II study of its recAP protein in patients with acute renal failure as well as to continue the development of an oral formulation of recAP for patients with ulcerative colitis.

Other posts that may interest you

Biotechnology is supported by investors.

Inveready bets on biotechnology, invests in Cuantum and AB-biotics in less than a month

Investors lose their fear of investing in biotechnology

If you are looking for financing for your company, contact us. Abra-Invest has a team of experts in alternative financing at your disposal. Call + 34 946424142 or fill in the contact form.


The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?